By Dr. Priya Nair, Health Technology Reviewer Last updated: May 14, 2026 SELECT Trial Reveals GLP-1 Medications Could Enhance Longevity Beyond Weight Loss In a remarkable finding from the SELECT trial, GLP-1 medications such as semaglutide have demonstrated a potential to recalibrate our understanding of longevity beyond mere weight loss. The trial discovered a striking … Read more
Discover how the SELECT trial indicates that GLP-1 medications might enhance longevity beyond weight loss.
Discover how the SELECT Trial reveals GLP-1 medications may enhance longevity beyond their weight loss capabilities, influencing future healthcare strategi
Discover how GLP-1 medications reveal profound longevity insights that extend beyond weight loss and reshape preventive medicine.
Explore how SELECT trial data reveals GLP-1 medications’ potential in boosting longevity beyond just weight loss, with significant cardiovascular benefits.
Discover how SELECT Trial data signals that GLP-1 drugs may impact longevity beyond weight loss, unveiling a $50 billion market opportunity.